Whalesbook
Supply Shocks and Tax Woes Batter MedTech
The Indian medical device sector is grappling with escalating costs from global events and internal tax issues. Tensions in West Asia have driven up costs for key materials like petrochemical-based polymers by as much as 50%. Industrial gas prices have doubled, and shipping costs have also increased, squeezing the slim profit margins on essential items such as syringes and catheters.
Manufacturers are also struggling with significant delays in getting back Goods and Services Tax (GST) they've paid on inputs. This is mainly because the industry pays 18% GST on raw materials and components but only 5% GST on finished medical devices. This difference means companies have substantial amounts of tax credit trapped, forcing them to rely on expensive bank loans to fund operations, particularly hurting small and medium-sized businesses.
This combination of rising expenses and blocked cash flow poses a threat to the sector's ambitious growth plans. India aims for the medical device market to reach $50 billion by 2030, but these current challenges could derail the nation's aspirations to become a major global manufacturing hub and impact millions of jobs.
Global Ambitions Meet Deep-Rooted Issues
India aims to become a global leader in medical technology manufacturing, targeting a significant share of the world market. Growth is expected to be fueled by rising healthcare spending and domestic demand. However, the country remains heavily dependent on imports for 70-85% of its medical devices, limiting the potential of its own manufacturing.
The inverted duty structure, where GST on inputs exceeds that on final products, has been a long-standing issue. It appears to have worsened for medical devices following recent tax changes that lowered taxes on finished goods without adjusting input taxes accordingly. This policy gap comes as other countries are actively working to secure their supply chains by diversifying manufacturing locations, presenting India with a prime opportunity.
Industry bodies like AiMeD and NATHEALTH have welcomed government initiatives to speed up GST refunds, such as releasing 90% upfront in low-risk cases from late 2025. However, these measures follow extended delays and may need to be broader to fully address the liquidity crunch.
The regulatory system for medical devices in India is evolving, moving towards international standards. However, it still presents complexities, particularly for smaller companies.
Weaknesses Exposed by Global Turmoil
India's medical device industry faces significant challenges due to its underlying structural weaknesses. A major concern is the heavy reliance on imported high-end equipment and specialized parts, which contradicts goals for self-sufficiency. Innovation also lags, with lower investment in research and development compared to global competitors.
Furthermore, the industry suffers from a shortage of skilled professionals. Access to capital for smaller firms is limited, hindering investments in advanced manufacturing. The current crisis, intensified by global events affecting supply chains, highlights the vulnerability of relying on petrochemicals from regions like West Asia. These disruptions can quickly lead to higher material costs and potential shortages.
The higher GST on inputs exacerbates this risk, creating a financial trap where blocked tax credits directly affect operations. While efforts are underway to expedite GST refunds, their effectiveness against ongoing supply chain disruptions and rising costs remains to be seen.
Industry calls for temporary customs duty relief on raw materials and components, and resistance to lower import duties on finished devices, underscore the delicate balance needed to support domestic production against international price competition.
Path Forward Requires Urgent Policy Action
Despite the current pressures, the Indian medical device industry's growth outlook remains strong, with projections for significant expansion by 2030. Government policies like the Production-Linked Incentive (PLI) scheme and the National Medical Devices Policy, 2023, aim to boost domestic manufacturing and innovation.
New initiatives to speed up GST refunds show a recognition of the urgent need to ease cash flow problems. However, the combination of global supply shocks and persistent tax policy issues presents a major obstacle.
For the sector to achieve its growth potential, swift and decisive policy action is crucial. This must not only address immediate cash flow issues but also resolve fundamental problems like the inverted duty structure and import dependency. Increased support for R&D, talent development, and streamlined regulations will be vital for India to transition from simply assembling devices to becoming a genuine MedTech innovator and manufacturing leader.